معرفی
Roles & Affiliations: Dakang Xu is a Researcher affiliated with Monash University and works at the Centre for Cancer Research, Hudson Institute of Medical Research. His research focuses on inflammatory responses, immune cell subsets, and tumor progression in cancer and inflammatory diseases. He has contributed to over 59 peer-reviewed publications, including high-impact journals like Nat Immunol, Immunity, and Nat Commun.
Research Interests: His work centers on the modulation of key regulators in immunity and cancer, including the role of cytokines, transcription factors (e.g., ATF3, PLZF), and signaling pathways (e.g., Wnt, NF-κB). He investigates tumor microenvironment dynamics, immune cell interactions, and therapeutic targets for cancers such as gastric, colorectal, and pancreatic cancers.
Projects & Grants: Dakang Xu has led or contributed to NHMRC-funded projects, including studies on cytokine signaling in systemic lupus erythematosus, activating transcription factor 3 (ATF3) in cancer progression, and the role of PLZF in antiviral immunity. His research spans mechanisms of inflammation, cellular senescence, and metabolic regulation in cancer.
Labs & Collaborations: Collaborations include teams at Monash University, Hudson Institute, and international institutions. His group employs advanced techniques like CRISPR screening, computational modeling (e.g., cell graph neural networks), and multi-omics analyses to study cancer biology and immunity.
